A fixed-dose combination of digestive enzyme supplement (Pancreatin) and an amino acid derivative (Ornithine) used primarily for the management of digestive insufficiency and associated symptoms like bloating and flatulence. Pancreatin provides exogenous lipase, protease, and amylase to aid digestion, while Ornithine is involved in the urea cycle and is believed to support detoxification and reduce ammonia load, potentially alleviating symptoms of digestive discomfort and fatigue.
Adult: One to two tablets/capsules, taken with each main meal or as directed by the physician. The dose should be swallowed whole with a glass of water, during or immediately after the meal.
Note: Swallow the tablet/capsule whole with plenty of water. Do NOT crush or chew. Take during or immediately after meals to synchronize with gastric emptying. Do not lie down immediately after taking. For optimal Pancreatin activity, it should not be taken with antacids or acid-suppressing drugs (PPIs, H2 blockers) simultaneously, as a higher gastric pH may cause premature release of enzymes.
Pancreatin: A porcine pancreatic extract containing lipase, amylase, and protease enzymes. It supplements deficient exocrine pancreatic secretions, facilitating the hydrolysis of fats into fatty acids and glycerol, starches into dextrins and sugars, and proteins into peptides and amino acids in the duodenum and small intestine. Ornithine: As L-Ornithine, it is a key intermediate in the urea cycle. It enhances the conversion of toxic ammonia into non-toxic urea in the liver via the ornithine cycle. It may also stimulate the synthesis of glutamine, another ammonia scavenger. The combined rationale is to improve digestion and reduce potential metabolic by-products (like ammonia from protein fermentation) that contribute to bloating and malaise.
Pregnancy: Category C: Animal reproduction studies have not been conducted. Use only if clearly needed and potential benefit justifies potential risk to the fetus. Limited human data.
Driving: No known effects on driving ability. However, if dizziness or headache occurs as a side effect, caution is advised.
| Antacids (Calcium/Magnesium Carbonate) | May neutralize gastric acid, potentially causing premature release and inactivation of non-enteric coated Pancreatin. Separate administration by 2 hours. | Moderate |
| Proton Pump Inhibitors (Omeprazole, Pantoprazole) | Increased gastric pH may affect the release profile of enteric-coated enzymes. Clinical significance variable; monitor efficacy. | Moderate |
| Acarbose/Miglitol | Theoretical interaction: Pancreatin contains amylase which may reduce the efficacy of these alpha-glucosidase inhibitors. Avoid concurrent use. | Major |
| Iron supplements (Ferrous Sulphate) | Pancreatic enzymes may impair iron absorption. Administer at different times of the day (separate by 2-3 hours). | Moderate |
| Folic Acid | Pancreatic enzymes may reduce folate absorption. Monitor folate levels with long-term use. | Moderate |
| Allopurinol/Febuxostat | Pancreatin increases purine load. May necessitate adjustment of urate-lowering therapy in gout patients. | Moderate |
Same composition (Pancreatin (100mg) + Ornithine (150mg)), different brands: